Proteomics and metabolomics-based identification of novel treatment strategies in pancreatic ductal adenocarcinoma
Introduction: Pancreatic ductal adenocarcinoma (PDAC) has very low survival rates that have not changed in over 40 years. Delay in diagnosis and the development of drug-resistance limits the effectiveness of current therapies, making identification of novel early detection and combination treatment strategies, extremel...